The recent publication that most appealed researchers’ attention was “Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer (23)”, whose citation can be dated from 2020 with an increasing trend. This evidence concerns the gene ERBB2 and breast carcinoma.